Next-generation multiple sclerosis therapies look beyond B cells 

Behind marketed MS therapies that suppress autoimmunity by targeting B cells broadly, next-wave programs are focused on more selectively stopping or reversing pathology at the site of disease.

Early trials, company launches, deals and translational publications reveal two main trends for the nerve-damaging autoimmune disease: immune suppressors whose effects are more targeted and concentrated than those of marketed therapies, and strategies to increase neuronal myelination. Multiple companies are also addressing neuronal function directly...